You are seeing these quotes based on previous browsing related to sectors such as
| Latest | Forecast | |
|---|---|---|
| Div Yield | 0.0% | n/a |
| Div Cover | n/a | n/a |
| Op Mrgn | -201.4% | n/a |
| ROCE | 0.0% |
| Latest | Forecast | |
|---|---|---|
| P/E | -1.7 | n/a |
| PEG | 0.0 | n/a |
| Price / Revenue | 6.7 | n/a |
| Price / Book value | 4.2 |
| Latest | Forecast | |
|---|---|---|
| Revenue | -60.8% | 0.0% |
| PBT | 0.0% | n/a |
| EPS | 0.0% | 0.0% |
| DPS | n/a | 0.0% |
| Year Ending | Revenue (£m) |
Pre-tax (£m) |
EPS | P/E | PEG | EPS Growth | Div | Yield |
|---|---|---|---|---|---|---|---|---|
| 2021-03-31 | 4.16 | -1.26 | -0.12p | -1,364.4 | 0.0 | n/a | n/a | 0.0% |
| 2022-03-31 | 4.80 | -1.33 | -4.60p | -13.0 | 0.0 | n/a | n/a | 0.0% |
| 2023-03-31 | 2.90 | -2.86 | -10.00p | -3.8 | 0.0 | n/a | n/a | 0.0% |
| 2024-03-31 | 1.14 | -2.29 | -3.90p | -1.0 | 0.0 | n/a | n/a | 0.0% |
| Fusion Antibodies validation project with US NIC progresses Sharecast News | 31 Jan |
|---|---|
| Fusion Antibodies reports positive recent trading Sharecast News | 08 Oct |
| Fusion Antibodies strengthens financial position despite revenue decline Sharecast News | 05 Sep |
| Update on U.S. Patent for OptiMAL® | 22-May-25 14:33 |
|---|---|
| Issue of shares to non-executive directors | 07-May-25 14:23 |
| Director/PDMR Shareholding | 06-May-25 23:12 |
| Holding(s) in Company | 06-May-25 23:12 |
| Trading update | 06-May-25 23:10 |